Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses

By sjmartinez • November 16, 2022

Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser CB, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. JCI Insight. 2022 Nov 15:e163471. doi: 10.1172/jci.insight.163471. Epub ahead of print. PMID: 36378539.

Tags: Adaptive immunity, covid-19, Immunology, Infectious Diseases, Publications

Related Posts

Social Networks Play a Complex Role in HIV Prevention Knowledge, Attitudes, Practices, and the Uptake of PrEP Through Transgender Women Communities Centered Around Three “Casas Trans” in Lima, Peru: A Qualitative Study

Temelkovska T, Moriarty K, Huerta L, Perez-Brumer A, Segura E, Passaro RC, Lake JE, Clark J, Blair C. Social Networks Play a Complex Role in ...

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy

Cartwright EJ, Pierret C, Minassian C, Esserman DA, Tate JP, Goetz MB, Bhattacharya D, Fiellin DA, Justice AC, Lo Re V 3rd, Rentsch CT. Alcohol ...

Safety and tolerability of tedizolid as oral treatment for bone and joint infections

Miller LG, Flores EA, Launer B, Lee P, Kalkat P, Derrah K, Agrawal S, Schwartz M, Steele G, Kim T, Kuvhenguhwa MS. Safety and tolerability ...